SecBot SecBot

CHRS drug pipeline

Coherus Oncology, Inc. · 3 rated drugs
$0.5060
−3.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.4%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
3
1 mixed · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. since October 2023.

LOQTORZI toripalimab-tpzi Updated Nov 9

What to watch

LOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.

Bull case
  • LOQTORZI is the only FDA-approved treatment specifically for nasopharyngeal carcinoma, a niche with limited competition and a clear medical need.
  • Six-year JUPITER-02 follow-up data showed LOQTORZI plus chemotherapy nearly doubled median overall survival (64.8 months vs chemotherapy alone), with a 38% lower risk of death.
  • Revenue is growing: Q2 2026 LOQTORZI net sales of $13.6M were up 15% sequentially and 92% year-over-year, with management guiding $57M-$62M for full-year 2026.
Bear case
  • NPC is a rare cancer, limiting LOQTORZI's peak sales potential to an estimated $150M-$200M by mid-2028, which is modest for a commercial biotech.
  • The PD-1 inhibitor market is intensely competitive, dominated by Merck's Keytruda and Bristol Myers' Opdivo, which have broad label approvals across many cancer types.
  • Coherus priced LOQTORZI at a roughly 20% discount to Keytruda, suggesting pricing pressure in the PD-1 class.
◆ mixed
Impact
PhasePhase 1b/2a
Time to marketTagmokitug is in Phase 1b/2a development. Even with an expedited development path, a registrational trial would need to be designed, enrolled, and read out before any regulatory filing, which typically takes several years for a novel oncology asset.

tagmokitug Updated Nov 9

What to watch

The next catalyst for tagmokitug is further clinical data from the TREGCHECK program, potentially in H1 2027, as Coherus pursues an expedited development path in esophageal cancer. The October 2026 interim data (75% ORR in 1L ESCC) was encouraging but the stock fell 23% on the day, suggesting the market wanted larger sample sizes or clearer registration path details. Watch for the company to outline specific registrational trial plans and timelines in upcoming investor events.

Bull case
  • Tagmokitug showed a 75% confirmed overall response rate (ORR) in first-line ESCC irrespective of PD-L1 status, and a 100% confirmed ORR in PD-L1-positive evaluable patients, which are compelling early efficacy signals.
  • Coherus announced a strategic prioritization plan (Nov 9, 2026) focusing all development efforts on tagmokitug/toripalimab for esophageal cancer with plans for expedited development, signaling strong internal conviction.
  • The analyst consensus is strongly bullish: 4 Strong Buy, 6 Buy, 0 Sell ratings, with a mean price target of $7.75 versus the current ~$0.82 stock price, implying massive upside if the drug advances.
Bear case
  • Despite a 75% confirmed ORR in 1L ESCC, CHRS stock fell 23% on the data release day (Oct 29, 2026), indicating the market found the interim data unconvincing or was disappointed by small sample sizes.
  • Tagmokitug is still in Phase 1b/2a; a registrational path and pivotal trial design have not been finalized, meaning any path to approval is likely years away.
  • The stock trades near its 52-week low ($0.732) with a market cap around $150M, and elevated short-sale volume (z-score 2.36) suggests persistent bearish positioning.
● neutral
Impact
PhasePhase 2
Time to marketUnclear. Casdozokitug is in Phase 2 development for hepatocellular carcinoma. No pivotal or registration-directed trial has been announced, and the program appears to have been deprioritized in favor of tagmokitug.

casdozokitug Updated Nov 9

What to watch

Watch for any update on the randomized Phase 2 study of casdozokitug + toripalimab + bevacizumab in first-line HCC, which was initiated in December 2024. The company's November 2026 strategic prioritization plan appears to focus on tagmokitug for esophageal cancer, so investors should monitor whether casdozokitug development continues or is formally deprioritized. The stock trades around $0.82 with a market cap near $156 million and has a mean analyst price target of $7.75, though coverage is stale (last analyst action August 2026).

Bull case
  • Casdozokitug is a first-in-class IL-27 antagonist with a novel mechanism that could address resistance to checkpoint inhibitors in HCC, a large market.
  • Final Phase 2 data showed a 17.2% complete response rate and 38% objective response rate in combination with atezolizumab/bevacizumab, which is notable in a difficult-to-treat cancer.
  • The randomized Phase 2 study combining casdozokitug with Coherus's own approved PD-1 inhibitor toripalimab could create a proprietary combination if successful.
Bear case
  • The original Phase 2 study (NCT05359861) was terminated as of October 2026, and the company's November 2026 strategic prioritization plan focuses on tagmokitug for esophageal cancer, suggesting casdozokitug has been deprioritized.
  • No pivotal or registration-directed trial has been announced, and no data readout date has been given for the randomized Phase 2 study.
  • Coherus has a small market cap (~$156 million) and limited commercial revenue (LOQTORZI sales of ~$14-15 million/quarter), raising questions about funding for multiple pipeline programs.

Other drugs in filings and trials

no drug report yet
  • YUSIMRY Last: Approval · Dec 17, 2021
  • UDENYCA Last: Approval · Nov 2, 2018

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Oct 27, 2023LOQTORZIApproval+9.8%+31.8%
Dec 17, 2021YUSIMRYApproval+3.4%+6.3%
Nov 2, 2018UDENYCAApproval−2.4%−13.3%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
casdozokitugTrial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaPhase 2Terminated · results30Jun 30, 2025